Top-Rated StocksTop-RatedNASDAQ:ASND Ascendis Pharma A/S (ASND) Stock Price, News & Analysis $161.57 +1.24 (+0.77%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Ascendis Pharma A/S Stock (NASDAQ:ASND) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ascendis Pharma A/S alerts:Sign Up Key Stats Today's Range$157.70▼$162.2250-Day Range$137.41▼$172.0652-Week Range$111.09▼$183.00Volume247,021 shsAverage Volume492,835 shsMarket Capitalization$9.85 billionP/E RatioN/ADividend YieldN/APrice Target$216.07Consensus RatingBuy Company OverviewAscendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Read More… Ascendis Pharma A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreASND MarketRank™: Ascendis Pharma A/S scored higher than 71% of companies evaluated by MarketBeat, and ranked 292nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingAscendis Pharma A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 15 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAscendis Pharma A/S has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ascendis Pharma A/S's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ascendis Pharma A/S are expected to grow in the coming year, from ($4.34) to $0.24 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ascendis Pharma A/S is -22.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ascendis Pharma A/S is -22.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.40% of the outstanding shares of Ascendis Pharma A/S have been sold short.Short Interest Ratio / Days to CoverAscendis Pharma A/S has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Ascendis Pharma A/S has recently decreased by 5.80%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAscendis Pharma A/S does not currently pay a dividend.Dividend GrowthAscendis Pharma A/S does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.40% of the outstanding shares of Ascendis Pharma A/S have been sold short.Short Interest Ratio / Days to CoverAscendis Pharma A/S has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Ascendis Pharma A/S has recently decreased by 5.80%, indicating that investor sentiment is improving significantly. News and Social Media3.3 / 5News Sentiment1.02 News SentimentAscendis Pharma A/S has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Ascendis Pharma A/S this week, compared to 7 articles on an average week.Search Interest11 people have searched for ASND on MarketBeat in the last 30 days. This is an increase of 450% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Ascendis Pharma A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Ascendis Pharma A/S insiders have not sold or bought any company stock.Percentage Held by Insiders40.00% of the stock of Ascendis Pharma A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Ascendis Pharma A/S's insider trading history. Receive ASND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address ASND Stock News HeadlinesAscendis Pharma A/S (NASDAQ:ASND) Receives Average Rating of "Buy" from BrokeragesMay 19 at 3:31 AM | americanbankingnews.comAscendis Pharma Announces Long-Term Phase 2 Trial Data Demonstrating Sustained Efficacy and Safety of TransCon PTH in Adults with HypoparathyroidismMay 14, 2025 | nasdaq.comTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape. May 20, 2025 | Paradigm Press (Ad)Ascendis Pharma A/S (NASDAQ:ASND) Receives "Overweight" Rating from Cantor FitzgeraldMay 14, 2025 | americanbankingnews.comAscendis Pharma A/S (ASND): Among the Best Growth Stocks to Buy and Hold for the Long TermMay 13, 2025 | insidermonkey.comNew Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)May 13, 2025 | globenewswire.comAscendis Pharma: New 4-Year Data Shows Sustained Response to TransCon PTH (Palopegteriparatide) Therapy in Adults with HypoparathyroidismMay 13, 2025 | finanznachrichten.deNew 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with HypoparathyroidismMay 12, 2025 | globenewswire.comSee More Headlines ASND Stock Analysis - Frequently Asked Questions How have ASND shares performed this year? Ascendis Pharma A/S's stock was trading at $137.67 at the beginning of the year. Since then, ASND stock has increased by 17.4% and is now trading at $161.57. View the best growth stocks for 2025 here. How were Ascendis Pharma A/S's earnings last quarter? Ascendis Pharma A/S (NASDAQ:ASND) posted its earnings results on Thursday, May, 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing analysts' consensus estimates of ($1.56) by $0.10. The biotechnology company had revenue of $123.97 million for the quarter, compared to the consensus estimate of $98.56 million. Read the conference call transcript. When did Ascendis Pharma A/S IPO? Ascendis Pharma A/S (ASND) raised $85 million in an initial public offering on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager. Who are Ascendis Pharma A/S's major shareholders? Ascendis Pharma A/S's top institutional shareholders include RA Capital Management L.P. (16.86%), Westfield Capital Management Co. LP (8.99%), T. Rowe Price Investment Management Inc. (5.01%) and Price T Rowe Associates Inc. MD (3.70%). How do I buy shares of Ascendis Pharma A/S? Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ascendis Pharma A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ascendis Pharma A/S investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Novo Nordisk A/S (NVO) and CrowdStrike (CRWD). Company Calendar Last Earnings5/01/2025Today5/20/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ASND CIK1612042 Webwww.ascendispharma.com Phone(457) 022-2244Fax45-3694-4010Employees640Year FoundedN/APrice Target and Rating Average Stock Price Target$216.07 High Stock Price Target$289.00 Low Stock Price Target$153.00 Potential Upside/Downside+33.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($6.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-409,120,000.00 Net Margins-104.54% Pretax Margin-102.64% Return on EquityN/A Return on Assets-39.23% Debt Debt-to-Equity RatioN/A Current Ratio1.17 Quick Ratio0.84 Sales & Book Value Annual Sales$368.70 million Price / Sales26.72 Cash FlowN/A Price / Cash FlowN/A Book Value($1.88) per share Price / Book-85.94Miscellaneous Outstanding Shares60,971,000Free Float36,413,000Market Cap$9.85 billion OptionableOptionable Beta0.41 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:ASND) was last updated on 5/20/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAI Firm Enters America's Largest Medicaid MarketNew York's $95B system just approved a new AI healthcare platform. Here's what to know. A major shift in U....i2i Marketing Group, LLC | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMemorial Day: 59% dividend from Bitcoin (No Crypto Needed)140% Dividends from stocks like Tesla? Discover How for Just $9! For Memorial Day, get the full details of ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascendis Pharma A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.